Company ProfilePremium

Clever Culture Systems Ltd (formerly LBT Innovations Limited)

Company Profile Analysis

Ticker: CC5.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Clever Culture Systems Ltd - Company showcase

Year Founded & Workforce

2004

Clever Culture Systems Ltd logo

Clever Culture Systems Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Clever Culture Systems Ltd Overview

Clever Culture Systems is an Adelaide-based micro-cap medical and laboratory technology company that has spent two decades automating microbiology laboratories. Its sole commercial platform, the APAS® Independence (Automated Plate Assessment System), uses imaging, artificial intelligence and machine learning to read, interpret and report microbiology culture plates after incubation. The company says it is the only US FDA-cleared AI technology for automated culture-plate reading. The platform was first built for clinical diagnostics, where adoption disappointed. A strategic reset in late 2023 pivoted the company toward pharmaceutical environmental monitoring (EM), the high-volume reading of settle and contact plates in sterile drug manufacturing. Since then CCS has won AstraZeneca as an anchor "land-and-expand" customer and has broadened its base to eight top-30 global pharma companies. These include AstraZeneca, Pfizer, Bristol Myers Squibb, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services and CSL Behring. The investment case rests on converting single-instrument evaluations into network-wide multi-instrument deployments while managing a thin cash buffer.


Company's own description

The company's standard boilerplate (Q4 FY26 Appendix 4C, 30 July 2026) describes CCS as a provider of intelligent automation solutions to microbiology laboratories, based in Adelaide. It says CCS has developed the APAS® Independence, which uses AI and machine-learning software to automate the imaging, analysis and interpretation of microbiology culture plates. It states that the technology is the only US FDA-cleared AI technology for automated culture-plate reading. It sells the product to pharmaceutical-manufacturing microbiology laboratories for reading environmental-monitoring plates, and to clinical laboratories as an in-vitro diagnostic for infectious diseases. Thermo Fisher Scientific is exclusive distributor to clinical customers in the US and selected European countries.

Independent characterisation

CCS is a single-product, single-segment capital-equipment-plus-software business with a razor/razor-blade-style revenue model:

Instrument sales (one-off): each APAS® Independence is sold outright (or, since FY26, leased). Management sizes the large-pharma opportunity at about A$0.5m in upfront sales per instrument. This is derived from its statement that 100 instruments equal about A$50m upfront (Q4 FY26 4C).

Annual software licences for analysis modules (recurring): AI "analysis modules" (settle plate, 55mm contact plate, clinical urine, MRSA and others) are licensed annually per instrument.

Maintenance and support (recurring): multi-year service contracts. The AstraZeneca contract carried seven years of maintenance and support (August 2024 ASX release).

Validation services (emerging): paid support to help customers validate APAS® into GMP-regulated routine use. A dedicated UK-based lead was hired in June 2026.

Leasing (new in FY26): CSL Behring took a five-year lease in June 2026.

Grants and R&D tax incentives (non-operating but material): e.g., A$0.74m CTCM matched-funding grant income in H1 FY25 and A$1.07m R&D Tax Incentive received in FY26.

Management states that annual recurring revenue (ARR), mainly high-margin software licences, exceeded A$1.3m per year at 30 June 2026 (Q4 FY26 4C). It frames the medium-term economics as about A$50m upfront plus A$10m ARR if its eight large pharma customers deployed 100 instruments. That implies roughly A$100k ARR per installed instrument at maturity (management estimate, not guidance).

Value-chain position

CCS designs the instrument, develops the AI software, and manages manufacturing, global sales and product development from Australia (H1 FY26 Note 10). It does not make culture media (plates). This is strategically relevant because Thermo Fisher, a dominant culture-media supplier, distributes the clinical version partly to pull through its own media sales (Biotech Daily, June 2022).

Customer types and end-markets

End-marketUse caseStatusRepresentative customers
Pharmaceutical manufacturing QC (environmental monitoring)Reading settle plates and contact plates from cleanroom monitoringPrimary growth market since March 2024AstraZeneca, Pfizer, BMS, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services (Patheon), CSL Behring, one unnamed top-30 pharma, a US single-site manufacturer
Clinical microbiology (IVD)Urine culture screening, MRSA screeningLegacy market; sales below expectations; Thermo Fisher inventory depleted in FY26US hospitals via Thermo Fisher; Labor Dr Wisplinghoff (Germany)

Strategy

Stated strategy (company themes)

"Land and Expand": win top-30 global pharma customers with single-instrument placements and evaluations (land), then deploy multiple instruments across their global sterile-manufacturing networks (expand). AstraZeneca, with eleven sales to date (Interim FY26), is the template.

FY26 objective: broaden and diversify the customer base beyond AstraZeneca. This was achieved: large pharma customers rose from four to eight (Q4 FY26 4C).

FY27 objective: the "sales expansion phase", converting existing customers into multi-unit deployments. Management sized this at up to 100 instruments (≈A$50m upfront, ≈A$10m ARR) across the eight large pharma customers, plus about 80 instrument opportunities among new qualified customers.

Initiatives in the last 24 months

InitiativeDateDetail
Pharma pivot and settle-plate moduleMar 2024Launched; co-developed with AstraZeneca
Contact-plate moduleCompleted 31 Aug 2025Enables full EM coverage; rolled out to installed base
Name and brand changeNov 2024LBT Innovations becomes Clever Culture Systems (CC5), aligning with the APAS commercial brand
Instrument leasing modelFY26First lease to CSL Behring (five years)
Paid evaluationsFY26Non-refundable deposits during six-month evaluations
Validation servicesJune 2026UK-based lead hired; new revenue stream
APAS Expert User Group2,026Customer-formed group of six large pharma members, meeting three to four times a year; potential collective voice to regulators
APAS Discovery DayJune 2026Held at AstraZeneca Macclesfield; customers from ten countries
Technology roadmapOngoingStreamlined plate processing, integration with customers' digital ecosystems (e.g., LIMS), and module refinement from real-world data
Capital structure clean-upNov 2025Option conversion raised A$3.2m; SAFA loan repaid
Working-capital debtJune 2026A$1.6m unsecured, 10% interest, 16m options attached

Targets and guidance

  • FY26 placement guidance (at least 11, matching FY25) was met (Q4 FY26 4C).

  • FY27: "sales growth expected", but no quantitative revenue or profit guidance.

  • ESG or cost-programme targets: not publicly disclosed.

Products & Services

Current commercial portfolio

Product / serviceDescriptionKey capabilitiesTarget customerLaunch / latest versionPricing model
APAS® Independence (instrument)Benchtop automated plate-reading instrument: loads, images and interprets incubated culture platesAI/ML image analysis; permanent digital plate image; consistent reads; FDA-cleared (clinical); off-the-shelf validated modules for both EM plate typesPharma QC labs; clinical microbiology labsFDA clearance c.2019–20; contact-plate hardware upgrade Aug 2025Outright sale (≈A$0.5m per unit implied by management) or five-year lease (from FY26)
APAS® Settle Plate Analysis Module (pharma, formerly "APAS PharmaQC")AI software to detect microbial growth on 90mm settle plates used in cleanroom EMCo-developed with AstraZeneca; AstraZeneca pilot reported that no plate with growth was missedSterile drug manufacturersLaunched March 2024Annual licence per instrument
APAS® 55mm Contact Plate Analysis ModuleAI software plus instrument enhancements for smaller contact platesContact plates are about 50% of EM plate volume; CCS says APAS is the only automated instrument with validated modules for both plate typesSterile drug manufacturersValidated and completed 31 Aug 2025Annual licence; hardware/software upgrade for existing customers
Clinical Urine Analysis ModuleScreens urine culture plates and triages negativesFDA-cleared with the instrumentClinical labs (US via Thermo Fisher; EU)c.2019–20Annual licence
MRSA Analysis ModuleScreens MRSA chromogenic platesFDA-cleared 2021; works on Thermo Fisher and BD mediaClinical labs2,021Annual licence
Maintenance and supportInstallation, qualification, servicingMulti-year (e.g., seven years for AstraZeneca)All customersOngoingAnnual or multi-year contracts
Validation servicesSupports customers through GMP evaluation and validationProgramme to shorten validation time; UK-based lead hired June 2026PharmaFormalised FY26Fee for service (pricing not disclosed)

Legacy and pipeline technologies (historical LBT portfolio)

TechnologyDescriptionStatus
MicroStreakAutomated culture-plate streaking and inoculation; LBT's first product, commercialised via bioMérieuxRights returned to LBT; not currently marketed
Automated Gram Stain Assessment (AGSA)AI interpretation of Gram-stain images—
WoundVueAI-assisted assessment of chronic wounds—
Biofilm detectionDetecting biofilms in the presence of mammalian tissue—
APAS urine/infection-control/AST extensionsAdditional clinical applicationsReferenced historically; not current priority

These appear in aggregator profiles of the company but are not featured in recent company disclosures. Their current status (active, shelved or licensed) is not publicly disclosed.

Financial Narrative

FY2026 audited results were not available. FY26 cash-flow data come from the unaudited Q4 FY26 Appendix 4C.

Income statement: notes and sources

Sources: StockAnalysis income statement (aggregator); FY22 Appendix 4E (net loss FY21 A$7.26m, FY22 A$6.64m confirmed); TipRanks/FY25 results (net profit A$1.68m confirmed); Simply Wall St/Yahoo (EPS FY25 A$0.001 vs FY24 A$0.004 loss). FY23 net loss includes the A$13.4m APAS impairment (Interim FY26 Note 1).

Margins

Revenue CAGR FY21–FY25 (ordinary revenue): about 48.6% a year (A$1.12m to A$5.46m). This is computed and flattered by a very low base.

Half-year bridge (most recent audited/reviewed data)

Source: H1 FY26 Interim Report (17 Feb 2026). Management attributes the A$2.3m pre-tax swing to (1) A$0.91m of grants and other income in the prior period that did not recur; (2) A$0.68m of staff costs capitalised on contact-plate development in the prior period, now expensed after the project completed on 31 Aug 2025; and (3) A$0.31m higher non-cash charges (depreciation and share-based payments).

Balance sheet

Sources: H1 FY26 Interim Report (30 Jun 2025 comparatives; 1 July 2024 equity A$2.423m); FY22 Appendix 4E (NTA); H1 FY25 report (NTA 30 Jun 2024).

Post-FY25 balance-sheet trajectory

Sources: H1 FY26 Interim; Q4 FY26 4C. A$1.68m (A$1.6m principal plus A$80k interest) falls due on 31 Dec 2026.

Intangibles detail (31 Dec 2025). The gross carrying amount is A$16.1m before impairment. This comprises A$13.4m of "pre-pharma" APAS development (fully impaired in FY23) and A$2.7m of capitalised contact-plate development. The directors have not reversed the A$13.4m impairment, citing insufficient "reasonable and supportable" evidence until the expand phase is proven. A reversal would be a material positive signal to watch.

Cash flow: notes and sources

Source: FY26 figures from the Q4 FY26 Appendix 4C (12-month year-to-date, unaudited). H1 FY25 operating cash flow was +A$0.30m and H1 FY26 +A$0.19m (Interim reports). The company reported two consecutive quarters of positive operating cash flow in H2 FY25 (TipRanks summary of quarterly).

Commentary on trends and drivers

  1. FY21–FY23, the clinical years. Revenue stalled at about A$1–2m a year while the business burned about A$7–8m of operating losses annually. This was consistent with the about A$7.5m annual cash burn cited in 2022 (Stockhead). Clinical labs adopted slowly despite FDA clearance and the Thermo Fisher partnership. The FY23 impairment (A$13.4m) recognised that the clinical business case could not support the capitalised asset base.

  2. FY24, the reset. Revenue fell 41% as clinical sales dried up, but the cost base was cut: operating loss narrowed from A$7.1m to A$4.7m. The Nov 2023 recapitalisation and SA loan restructure bought time to finish the AstraZeneca-co-funded settle-plate module.

  3. FY25, the inflection. Nine-plus AstraZeneca units and early BMS and other pharma sales lifted ordinary revenue to A$5.46m. Combined with grant income and R&D tax benefits, the company booked its first net profit (A$1.68m). The quality of earnings was moderate: operating loss was still A$1.17m, so the profit relied on tax benefits and grants.

  4. FY26, broadening but lumpier. Placements were flat at 11. But only six were fully recognised as sales; two were partial deposits on evaluations, one was a lease and two were clinical sales via Thermo Fisher. H1 FY26 swung to a A$1.3m loss, and FY26 operating cash flow was -A$2.6m (unaudited). The company's strategy deliberately trades near-term revenue (evaluations and leases) for a broader customer base.

  5. Going concern. The auditor flagged a material uncertainty about going concern in FY22 and again at H1 FY26. At 30 June 2026, the 4C showed only 1.08 quarters of funding, with reliance on A$3.4m of expected inflows. These comprise A$1.8m of receivables, a A$0.7m R&D tax incentive and A$0.9m of committed customer inflows.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipFunction

Clever Culture Systems Ltd

Australia

Listed parent

R&D, manufacturing management, global sales, corporate

Clever Culture Systems AG

Switzerland

100% (since Dec 2021; previously a 50:50 JV with Hettich)

Original APAS commercialisation vehicle

Revenue stream (AUD K)

Revenue stream (AUD K)H1FY25H1FY26

Instrument and accessories sales

2,4011,963

Licence fees

217302

Maintenance services

135270

Consulting services

700

Total revenue

2,8232,535

Government grants (other income)

7360

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue, ordinary (AUD Mn, aggregator)

1.122.132.131.265.46

Total revenue incl. other income (AUD Mn, company)

2.112.90—1.716.63

YoY growth, ordinary revenue (%)

—89.50.2-41.1334.8

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue, ordinary (AUD Mn)

1.122.132.131.265.46

Cost of revenue (AUD Mn)

—0.950.430.151.50

Gross profit (AUD Mn)

—1.181.711.113.96

SG&A (AUD Mn)

4.985.464.704.524.05

R&D expensed (AUD Mn)

0.220.240.300.670.07

Operating income (AUD Mn)

-6.66-7.90-7.14-4.74-1.17

Net income (AUD Mn)

-7.26-6.64-22.52-3.741.68

EPS basic (A$ cents)

———-0.40.1

Dividends per share (AUD)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

—55.480.388.172.5

Operating margin (%)

-594.6-370.9-335.2-376.2-21.4

Net margin (%)

-648.2-311.7-1,057.3-296.830.8

Income Statement and Per-Share Data (H1FY25–H1FY26)

Metric (AUD K)H1FY25H1FY26

Revenue

2,8232,535

Other income

94527

Cost of sales

755452

Employee benefits expense

1,3222,115

Corporate expenses

453475

Depreciation and amortisation

155303

Profit/(loss) before tax

621-1,684

Income tax benefit

488365

Net profit/(loss)

1,109-1,319

EPS basic (A$ cents)

0.07-0.07

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2024FY2025

Total assets (AUD Mn)

———10.77

Cash and equivalents (AUD Mn)

——2.351.27

Inventory (AUD Mn)

———1.43

Intangible assets (AUD Mn)

———2.45

Borrowings, current (AUD Mn)

———0.18

Borrowings, non-current (AUD Mn)

———0.80

Lease liabilities (AUD Mn)

———1.24

Net debt incl. leases (AUD Mn)

———0.95

Total equity (AUD Mn)

——2.425.65

Working capital (AUD Mn)

———2.91

NTA per share (A$ cents)

4.100.880.160.16

Balance Sheet

Metric (AUD Mn)30Jun202531Dec202530Jun2026

Cash

1.273.101.69

Borrowings (excl. leases)

0.9801.50

Inventory

1.432.16—

Total equity

5.658.01—

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD Mn)

————-2.57

Receipts from customers (AUD Mn)

————4.90

Capex incl. capitalised IP (AUD Mn)

————0.48

Free cash flow (AUD Mn)

————-3.05

Equity raised / options exercised (AUD Mn)

————3.25

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025H1FY26 (31 Dec 2025)Comment

ROE (%)

41.6

n/m

Uses average equity A$4.03m; inflated by tax benefits and grants

ROA (%)

15.6

n/m

Uses end assets

Current ratio (x)

2.232.81

Current assets / current liabilities

Debt/equity incl. leases (x)

0.390.16

Debt-free ex-leases at Dec 2025; new A$1.6m loan in June 2026

Net debt/EBITDA

n/m

n/m

EBITDA negative or not disclosed

Interest coverage

n/m

n/m

Operating loss

Asset turnover (x)

0.51

n/m

Revenue / total assets

Revenue by Region

Region (AUD K)H1FY25H1FY26Growth (%)

United States

49378960.0

Europe

1,4511,5899.5

Australia

447143-68.0

Asia

43214-96.8

Total

2,8232,535-10.2

Revenue by Region and Revenue by Region (%)

MetricFY2025H1FY25H1FY26

AstraZeneca revenue (AUD K)

—1,730865

AstraZeneca share of revenue (%)

806134

Share Price History

DatePrice (AUD)Market cap (AUD Mn)Source

Jun 2022

0.07524.0

Biotech Daily

7 Aug 2024

0.021 (intraday 0.027)

—

Motley Fool

6 Sep 2024

0.01524.5

Biotech Daily

Nov 2024

—28

InDaily

Mid/late 2025

about 0.027 (52-week range 0.012–0.037)

56.6–63.5

Yahoo; TipRanks

17 Feb 2026

0.029—

InvestSMART

30 Apr 2026

0.022—

InvestSMART

30 Jul 2026

0.017

about 37 (implied)

InvestSMART

Valuation Snapshot

MultipleValueBasis

EV/Sales (FY25)

about 7.0x

Market cap ≈A$37m, plus A$1.5m debt and A$1.3m leases, less A$1.7m cash (≈A$38m EV), over FY25 revenue A$5.46m

EV/ARR

about 29x

EV ≈A$38m / ARR A$1.3m

P/E

n/m

Loss-making (H1 FY26)

EV/EBITDA

n/m

Negative EBITDA

P/B

about 4.6x

Market cap ≈A$37m / equity A$8.0m (Dec 2025)

Capital Markets

ItemStatus

Analyst consensus

No published analyst coverage, rating or price target (Moomoo shows "No Data")

Dividend history and policy

No dividends ever paid; none proposed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

A$1.6m principal plus A$0.08m interest due 31 Dec 2026 (unsecured); lease liabilities A$1.31m (Dec 2025); credit card facility A$50k

Options overhang

About 129m options and performance shares at 31 Dec 2025 (exercise prices mostly A$0.014–0.033), plus 16m lender options from 1 Jul 2026

Analyst Conclusions

Management guidance

  • Sales growth expected in FY27, driven by existing customers and the qualified pipeline. No numeric guidance.

  • Expected cash inflows of at least A$3.4m over Q1–Q2 FY27, with up to A$2.6m in Q1 (Q4 FY26 4C).

  • No consensus estimates exist.

Bull case

  1. Customer base doubled to eight top-30 pharma companies. Even modest expansion (e.g., 20 extra units at about A$0.5m each) would roughly double FY25 revenue and push ARR toward A$3m.

  2. Proven expand template. AstraZeneca went from pilot to eleven units in about two years. Six large pharma customers now share experience through the Expert User Group, which could shorten others' validation cycles.

  3. Rising revenue quality. Recurring licence and maintenance revenue is growing at 39–100%, and the full EM offering (settle plus contact) removes a key purchasing objection.

Bear case

  1. Funding fragility. Only 1.08 quarters of funding, a A$1.68m bullet repayment in December 2026 and a going-concern emphasis point to probable further dilution at depressed prices.

  2. Flat placements despite more logos. Eleven placements in both FY25 and FY26, with FY26 including evaluations, a lease and final Thermo clinical units. Land has not yet produced expand.

  3. Competitive and structural friction. Incumbents bundle media and automation, validation is resource-constrained, and the clinical channel has stalled.

Key catalysts and monitorables (next 12 months)

  • Publication of the FY26 audited results, the going-concern wording and any impairment reversal.

  • Collection of the A$3.4m expected inflows in Q1–Q2 FY27 and repayment or refinancing of the December 2026 loan.

  • Conversion of CSL Behring and the unnamed pharma evaluation into purchases; first multi-unit orders from Pfizer, BMS, Novo Nordisk or Boehringer Ingelheim.

  • ARR progression above A$1.3m; validation-services revenue.

  • Status of the Thermo Fisher US distribution agreement (five-year term from Sep 2021).

  • Lead generation from the October–November 2026 conferences.

  • Any capital raise (size, price, dilution).

Analyst verdict

Clever Culture Systems has done what LBT Innovations could not do for a decade: find a market that wants its technology. The pivot from clinical diagnostics to pharmaceutical environmental monitoring has been validated by the customers that matter most. AstraZeneca has bought eleven instruments and its programme won an industry award. Pfizer, BMS, Novo Nordisk, Boehringer Ingelheim, Thermo Fisher Pharma Services and CSL Behring have all placed or evaluated APAS. With settle- and contact-plate modules both validated, the product gap is closed. The question is no longer whether APAS works but how fast regulated manufacturers will deploy it across their networks.

That question is now the entire investment case, and the evidence is incomplete. FY26 delivered breadth rather than depth: placements were flat at eleven, revenue fell in H1, and the business returned to losses after a grant- and tax-assisted FY25 profit. Management's A$50m-plus-A$10m-ARR opportunity within existing customers is plausible in a multi-year frame but unquantified for FY27. Customer-side validation bottlenecks are acknowledged and structural.

The balance sheet is the binding constraint. With A$1.7m cash, about one quarter of funding, a A$1.68m loan due 31 December 2026, an auditor's going-concern emphasis, a large options overhang and about 2.18bn shares on issue, shareholders should expect further capital management. Its terms will depend heavily on Q1–Q2 FY27 receipts and new orders. At about 7x trailing sales and roughly 29x ARR, the market already prices some expansion success.

Verdict: a high-risk, binary micro-cap with genuine product-market validation and a credible but unproven growth path. It is suitable only for speculative capital that can withstand dilution. The decisive monitorables are the first multi-unit orders from a non-AstraZeneca customer, conversion of the two paid evaluations, and how the December 2026 maturity is resolved. Positive outcomes on all three would materially de-risk the story. Failure on any would likely force a dilutive raise at weak prices.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / notesIndependence

Rebecca Wilson

Non-Executive Chair

Services from July 2023; Chair from Dec 2023

Independent

Brenton (Brent) Barnes

CEO and Managing Director

—

Executive

Daniel Hill

Non-Executive Director

—

Not disclosed (presumed independent)

Ian Wisenberg

Non-Executive Director

Appointed Q1 FY25 (Jul–Sep 2024); described as a US pharmaceutical leader; takes part of his fees in shares

Not disclosed (presumed independent)

Governance Overview

ElementDetailSource

CEO short-term incentive

Maximum cash bonus 30% of salary; FY25 bonus A$91,000, taken as 3,545,581 shares at A$0.0258 VWAP

Interim FY26 Note 7

CEO long-term incentive

40m options (exercise A$0.024, vest 10 Jun 2027, expire 10 Dec 2028; fair value A$473k) plus 10m performance shares (vest 10 Dec 2028 subject to a A$0.07 share-price hurdle; fair value A$130k); approved 14 Nov 2024 after the prior LTI was voluntarily relinquished

Interim FY26 Note 8

Executive LTI

40m options on the same terms as the CEO (issued 15 Jan 2025)

Interim FY26 Note 8

NED options

Wilson 3.81m; Hill 2.31m; Wisenberg 2.31m (exercise A$0.014; expire 10 Dec 2027)

Interim FY26 Note 8

Quarterly director cash payments

A$125,000 in Q4 FY26 (MD salary plus NED fees)

Q4 FY26 4C

Competitive Landscape

Key Competitors

CompetitorSegment overlapOfferingRelative positioning vs APAS

Rapid Micro Biosystems (Nasdaq: RPID)

Pharma EM and QC

Growth Direct automated incubation, imaging and enumeration

—

bioMérieux

Pharma QC and clinical

Industrial microbiology portfolio including EM data software; clinical lab automation

Global incumbent; former MicroStreak partner

Copan Diagnostics (with partners)

Clinical (some pharma)

WASPLab with PhenoMATRIX AI plate reading

Leading clinical full-lab automation; competes for clinical AI plate reading

BD (Becton Dickinson)

Clinical

BD Kiestra lab automation with imaging and AI reading apps

Clinical full-lab automation at large scale

Merck KGaA / MilliporeSigma

Pharma QC

EM media, monitoring systems, rapid micro methods

Media plus workflow incumbent

Sartorius

Pharma QC

Microbial QC instruments and consumables

Adjacent

Charles River Laboratories

Pharma QC

Microbial QC testing and rapid methods

Adjacent (services and rapid methods)

Thermo Fisher Scientific

Media; also distributor and customer

Culture media; distributes APAS clinically; Thermo Pharma Services is a customer

Partner-competitor dynamic

Interscience / Synbiosis / Redberry and other plate-counting and imaging vendors

Pharma QC

Colony counters and imaging

Lower-cost, less validated niche

Manual reading (status quo)

All

Trained microbiologists reading plates

The real competitor; inertia and validation burden

Peer Comparison FY2025

CompanyRevenueGrowthGross marginR&D intensityNote

Clever Culture Systems

A$5.46m (FY25)

+335% (FY25)

72.5% (FY25)

Low expensed; material capitalised

Verified (aggregator plus filings)

Recent Developments

--

Company Snapshot

$1.6M

Revenue

$21.5M

Market Cap

2004

Founded

Adelaide, Australia

Headquarters

SWOT Analysis

Strengths

  • Regulatory moat: the company states it is the only US FDA-cleared AI technology for automated culture-plate reading (Q4 FY26 4C).
  • Blue-chip references: eight top-30 pharma customers at June 2026, up from four (Q4 FY26 4C).
  • Anchor proof point: AstraZeneca has bought eleven instruments, and its programme won the Professor Wallhäußer 2026 Award (Interim FY26; ShareCafe).
  • Complete EM offering: validated settle- and contact-plate modules; contact plates are about 50% of EM volume (Interim FY26).
  • Recurring revenue build: ARR above A$1.3m; H1 FY26 licence +39% and maintenance +100% (Q4 4C; Interim Note 2).
  • High gross margin: 72.5% in FY25 (aggregator), with software-heavy recurring lines.

Weaknesses

  • Going-concern material uncertainty in the H1 FY26 auditor review (HLB Mann Judd).
  • Thin liquidity: A$1.7m cash at 30 Jun 2026 and 1.08 quarters of funding (Q4 FY26 4C).
  • Short-term debt maturity: A$1.68m due 31 Dec 2026 at 10% interest (Q4 4C).
  • Revenue concentration: AstraZeneca was about 80% of FY25 sales (ShareCafe).
  • Lumpy, small revenue base: H1 FY26 revenue down 10%, swinging to a A$1.32m loss (Interim FY26).
  • Failed clinical market: A$13.4m impairment in FY23; Thermo Fisher clinical inventory exhausted (Interim; Q4 4C).

Opportunities

  • Expand phase: up to 100 instruments within existing customers, worth about A$50m upfront plus A$10m ARR (management estimate).
  • New-customer pipeline: about 80 qualified instrument opportunities.
  • Validation services as a new revenue line (UK lead hired June 2026).
  • Leasing model lowers customers' capex barriers (CSL five-year lease).
  • Mid-market manufacturers: a US single-site sale shows the market extends beyond the top-30.
  • Impairment reversal: a potential A$13.4m reversal if expand-phase forecasts become supportable (Interim Note 1).

Threats

  • Dilution risk: about 2.18bn shares on issue, plus options and performance shares (about 129m at Dec 2025) and 16m new lender options.
  • Large competitors with bundled media and automation (bioMérieux, BD, Merck, Rapid Micro).
  • Evaluation attrition: two FY26 placements are paid evaluations that may not convert.
  • Validation friction slows deployment (management acknowledges this).
  • Thermo Fisher distribution term: the five-year US agreement from Sep 2021 is approaching its end; renewal not disclosed.
  • FX: revenue is mainly in US$, € and £ against an A$ cost base; FX swings were visible (A$178k gain H1 FY25; A$41k loss H1 FY26).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q4 FY25 (Apr–Jun 2025)Delivery of the additional four AstraZeneca instruments ordered in early 2025Completes the AstraZeneca expansion tranche
Q3–Q4 FY25Second consecutive quarter of positive operating cash flow; pipeline of 40+ active opportunitiesEvidence of commercial traction
22 May 202511.5m options issued to an investor-relations consultant (exercise A$0.025)Investor-relations push
Aug 2025FY25 results: revenue and income A$6.63m (+287.7%); NPAT A$1.68mFirst annual profit
31 Aug 2025Contact-plate module validation completedFull EM solution
Jul–Sep 2025 (Q1 FY26)Novo Nordisk and Boehringer Ingelheim placements; AstraZeneca and BMS installations completedCustomer diversification
1 Oct 202581.7m new shares quoted following option exercisesCapital inflow
30 Oct 2025Q1 FY26 4C: cash A$1.4m; A$4.1m of expected inflows over two quarters; share price later weakensCash visibility
Oct–Nov 2025Conferences in the US, Europe, Australia and South Korea, with customer presentations by AstraZeneca, BMS and PfizerThird-party validation
15 Nov 202599.6% of CC5OA options exercised (A$3.2m)Recapitalisation
Nov 2025SAFA loan (A$0.975m remaining) fully repaidDebt-free
17 Nov 2025AGM, all resolutions passed; investor open dayGovernance
3 Dec 2025CEO bonus shares issuedAlignment
23 Dec 20252.5m options exercised at A$0.014Minor
15 Jan 2026Investor-relations consultant options vestMinor
7 Feb 20264.2m retention performance shares convertMinor dilution
17 Feb 2026H1 FY26 results: revenue A$2.54m (-10%); net loss A$1.32m; cash A$3.1m; going-concern emphasis; share price falls from about 2.9cNegative market reaction
24 Feb 2026Trade press (Cleanroom Technology) covers big-pharma additionsVisibility
Q3 FY26 (Jan–Mar 2026)Three new orders; Pfizer and Thermo Fisher among FY26 customers; installed base reaches 30Momentum
2026AstraZeneca's APAS programme wins the Professor Wallhäußer 2026 AwardGMP credibility
30 Apr 2026Q3 4C: cash A$2.0m; nine placements year-to-date; two top-20 pharma deals in advanced contractingGuidance reaffirmed
June 2026CSL Behring five-year lease installed at Broadmeadow, MelbourneSeventh large pharma customer
June 2026Unnamed top-30 pharma begins six-month paid evaluationEighth large pharma customer
June 2026US single-site manufacturer purchases one APASMarket broadening beyond top-30
June 2026APAS Discovery Day and first in-person Expert User Group at AstraZeneca MacclesfieldEcosystem building
June 2026UK-based validation-services lead hiredNew revenue stream
30 Jun 2026A$1.6m unsecured loans at 10% interest, due 31 Dec 2026 (A$1.68m including interest)Liquidity bridge
1 Jul 202616m unlisted options issued to lenders (exercise A$0.033 per the 4C narrative; the 4C facility note says A$0.33, likely a typo; expiry 30 Jun 2028)Dilution; note the discrepancy
30 Jul 2026Q4 FY26 4C: eight large pharma customers; 34-unit base; ARR above A$1.3m; cash A$1.7m; 1.08 quarters of fundingKey data point
3 Aug 2026Investor conference callDisclosure
Aug–Sep 2026FY26 Appendix 4E / annual report due; not located in public sources at cut-offMonitor
Oct–Nov 2026Four major conferences planned (Australia, Europe, UK, US) with oral presentationsLead generation

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from AUD 2.8 Mn in 2025 to AUD 2.5 Mn in 2026.
Clever Culture Systems Ltd — Income Statement: Revenue & Gross Profit
Series (AUD Mn)20252026
Revenue2.82.5
Cost of sales0.80.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Clever Culture Systems, Quarterly Activities and Appendix 4C, quarter ended 30 June 2026 (30 Jul 2026), via investorpa.com
  2. Clever Culture Systems, Appendix 4D Interim Financial Report, H1 FY26 (17 Feb 2026), via announcements.asx.com.au
  3. Clever Culture Systems, Appendix 4D, H1 FY25 (21 Feb 2025), via announcements.asx.com.au
  4. LBT Innovations, Q1 FY25 4C (28 Oct 2024): Q2 FY24 4C (22 Jan 2024) · FY22 Appendix 4E (29 Aug 2022), via asx.com.au
  5. InvestSMART summaries of the Q3 FY26 4C (30 Apr 2026), Q4 FY26 4C (30 Jul 2026), H1 FY26 (17 Feb 2026) and Q1 FY26 4C (30 Oct 2025)
  6. ShareCafe, "Clever Culture Systems Builds Pharma Momentum" (30 Apr 2026)
  7. Cleanroom Technology (24 Feb 2026): StockWireX (Jul 2026)
  8. TipRanks announcement summaries (FY25 results: Appendix 2A quotations)
  9. StockAnalysis.com income statement (aggregator): Yahoo Finance · Simply Wall St · Morningstar · Moomoo; marketcapof.com
  10. Motley Fool / Market Herald / MT Newswires (7 Aug 2024): InDaily (18 Nov 2024) · Livewire (Nov 2023)
  11. Biotech Daily "Dr Boreham's Crucible" (17 Jun 2022; 6 Sep 2024): Stockhead
  12. PR Newswire / FNArena (27 Sep 2021): FNN interviews · Biotech Dispatch · BioSpectrum Asia (26 Jun 2013) · BioMelbourne (10 Jun 2016) · Smallcaps.com.au

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.